ARTICLE - POSACONAZOLE LEVELS IN PATIENTS TAKING THE DELAYED-RELEASE TABLETS VERSUS THE ORAL SUSPENSION

A retrospective comparison

15/06/2015 - This retrospective cohort study included 93 patients initiated on posaconazole between 2012 and 2014 and had at least one serum posaconazole level measured. The primary measure was the proportion of patients achieving an initial therapeutic level (> 700 ng/mL). An initial therapeutic posaconazole level was seen in 29 of 32 (91%) patients receiving tablets and 37 of 61 (61%) patients receiving suspension (p = 0.003). Among patients with a steady state level measured 5 to 14 days after initiation, a therapeutic level was observed in 18 of 20 (90%) patients receiving tablets and 25 of 43 (58%) patients receiving suspension (p = 0.01). In these patients, the median posaconazole level of the tablet cohort (1655 ng/mL) was twice that of the suspension cohort (798 ng/mL) (P=0.004).

Posaconazole levels in patients taking the delayed-release tablet versus the oral suspension: a retrospective comparison

Durani U, Tosh PK, Barreto JN, Estes LL, Jannetto PJ, Tande AJ.

Antimicrob Agents Chemother. 2015 Jun 8

Find this article here

RECENT NEWS | ARCHIVE